Pennsylvania Managed Care Companies Push For Higher Medicaid Reimbursements

Insurance companies operating managed care plans under Pennsylvania’s Medicaid program are objecting to a proposed payment increase that they say is too low to keep up with growing medical expenses, the Pittsburgh Post-Gazette reports. Gov. Ed Rendell’s (D) fiscal year…

Read More

San Francisco Chronicle Examines Use Of Pill-Splitting Programs By Health Insurers

The San Francisco Chronicle on Tuesday examined how several large insurers are “encouraging patients to save money by splitting their pills in half.” Consumers can save on copayments by cutting pills in half because pharmaceutical companies typically charge the same…

Read More

Some Patient Groups Have Financial Ties To Pharmaceutical Companies

The Philadelphia Inquirer on Sunday examined how “many patient groups and drug companies maintain close, multimillion-dollar relationships while disclosing limited or no details about the ties.” According to the Inquirer, “such coziness raises questions about the impartiality of groups that…

Read More

Canadian Health Minister Clement Notes Progress At G8 Health Ministers Meeting

Canadian Health Minister Tony Clement was pleased with the outcome of discussions at the first-ever meeting of G8 Health Ministers in Moscow. Ministers renewed their international commitment to combat avian influenza and prevent and prepare for a possible human pandemic…

Read More

Abbott’s HUMIRA(R) (Adalimumab) Receives Positive Opinion From European Medicines Agency For The Treatment Of Ankylosing Spondylitis

Abbott today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), granted a positive opinion recommending approval of HUMIRA(R) (adalimumab) for the treatment of severe active ankylosing spondylitis. The…

Read More

Abbott’s New Tablet Formulation Of Kaletra(R) (Lopinavir/Ritonavir) Receives Positive Opinion From The European Medicines Agency

Abbott announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued a positive opinion recommending approval of a new, more convenient tablet formulation of its protease inhibitor…

Read More

Pharmacokinetic Data For Nastech’s Intranasal Parathyroid Hormone (PTH1-34) Demonstrated Similar Profile To Approved Injectable Product

Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) presents data today from a Phase I pharmacokinetic study of Parathyroid Hormone (PTH1-34) nasal spray demonstrating a similar pharmacokinetic profile to the approved subcutaneous product, Forteo(R) (teriparatide). The data are being presented at the…

Read More